Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431 on ClinicalTrials.gov · last registry update 2026-02-19

A small phase 3 — 57 participants, against a typical 424. The sponsor logged completion for December 2019. Primary outcome, as filed: Galectin-3. exenatide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Baylor Research Institute
Sponsor type: Other
Enrollment: 57
Started: 2015-11
Primary completion: 2019-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Galectin-3

Conditions studied

Type 2 Diabetes Mellitus · Chronic Kidney Disease · Left Ventricular Diastolic Dysfunction

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.